Regeneron Pharmaceuticals Inc (REGN)
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (83%) **Content type:** Clinical